论文部分内容阅读
目的:观察米非司酮与孕三烯酮应用于盆腔子宫内膜异位症术后患者巩固治疗的疗效。方法:选择2008年6月～2009年6月在江山市中医院进行保守性手术治疗并经病理证实为盆腔子宫内膜异位症患者68例,随机分为两组:米非司酮组34例,给予米非司酮口服,12.5 mg/天;孕三烯酮组34例,给予孕三烯酮口服2.5 mg,每周2次。两组均于术后1周开始用药,疗程6个月;定期随访。结果:米非司酮及孕三烯酮组患者持续治疗半年,与治疗前比较,各组子宫内膜异位症引起的痛经等各种疼痛症状得到明显改善(P<0.05),随访结果显示,米非司酮及孕三烯酮组症状完全缓解率分别为85.2%和88.2%,两组复发率分别为5.9%和2.9%,两组疗效及复发率比较差异无统计学意义(P>0.05)。患者的不良反应米非司酮显著小于孕三烯酮。结论:米非司酮与孕三烯酮用于盆腔子宫内膜异位症手术后巩固治疗,安全、有效、不良反应轻。
Objective: To observe the effect of mifepristone and gestrinone in the treatment of postoperative patients with pelvic endometriosis. Methods: Sixty-eight patients with pelvic endometriosis who underwent conservative surgery in Jiangshan Hospital of Traditional Chinese Medicine from June 2008 to June 2009 were randomly divided into two groups: mifepristone group 34 For example, given mifepristone oral, 12.5 mg / day; gestrinone group of 34 patients, given gestrinone oral 2.5 mg twice a week. Two groups were started 1 week after surgery, treatment for 6 months; regular follow-up. Results: The patients in mifepristone and gestrinone treatment groups continued to treat for six months. Compared with those before treatment, various pain symptoms such as dysmenorrhea caused by endometriosis in each group were significantly improved (P <0.05), and the follow-up results showed , And the complete remission rates of mifepristone and gestrinone group were 85.2% and 88.2% respectively, the recurrence rates of the two groups were 5.9% and 2.9%, respectively. There was no significant difference in the curative effect and recurrence between the two groups (P> 0.05). Adverse reactions to patients Mifepristone was significantly less than gestrinone. Conclusion: Mifepristone and Gestrinone are safe and effective in the treatment of postoperative pelvic endometriosis. The adverse reactions are mild.